Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2018-11-13 Interim / Quarterly Rep…
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q3 2018
2018-11-13 English
FORM 10-Q/A
Interim / Quarterly Report Q1 2018
2018-09-28 English
FORM 10-K/A
Annual Report FY 2017
2018-09-28 English
PRIMARY DOCUMENT
Director's Dealing
2018-09-26 English
FORM 424(B)(3)
Capital/Financing Update Classification · 95% confidence The document is a Form 424(b)(3) prospectus filed pursuant to Rule 424(b)(3) under the Securities Act, which is used for registering securities for resale by selling stockholders. It details the resale of shares of common stock issuable upon exercise of warrants and conversion of preferred stock. The document includes information about the selling stockholders, the securities offered, risk factors, and other disclosures typical of a prospectus for secondary offerings. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a regulatory filing unrelated to securities offerings. The document is a capital/financing update related to the resale registration of shares by selling stockholders. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support a high confidence in this classification.
2018-09-25 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions a press release attached as Exhibit 99.1 but does not contain detailed financial statements or substantive financial data itself. The document length is only 2640 characters, which is short and consistent with an announcement rather than a full report. There is no indication that this is an earnings release, annual report, or other detailed financial filing. Therefore, this is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-09-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.